We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JDEP:EURONEXT AMSTERDAMJDE Peet's NV Analysis

Data as of 2026-07-10 - not real-time

$16.51

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

JDE Peet's is trading at $16.51, which sits below its 20‑day (≈$16.98), 50‑day (≈$17.28) and 200‑day (≈$18.21) simple moving averages, signalling a sustained bearish bias. Technical momentum is weak: the RSI is around 38, the MACD line trails its signal and the histogram is negative, and daily volume is shrinking, indicating limited buying pressure. Volatility remains elevated at roughly 21% over the past month, yet the stock’s beta is exceptionally low (≈0.11), suggesting price moves are largely idiosyncratic rather than market‑driven. Fundamentally, the company delivers modest revenue growth (≈5%) and a dividend yield of 2.55% with a payout ratio near 45%, which supports dividend sustainability, but the price‑to‑earnings multiple of ~18 and a DCF‑derived fair value of only $6.5 imply the stock is significantly overvalued. Debt levels are notable, with a debt‑to‑equity ratio near 50%, though cash generation (free cash flow ≈$0.62 bn) remains healthy. The recent share‑buyback of 500k shares at €24.28 under a €250 m programme shows management confidence, yet the repurchase price is well above the current market level, limiting immediate upside. Overall, the defensive consumer‑staples positioning and steady dividend provide a cushion, but technical weakness, overvaluation and liquidity constraints dominate the near‑term outlook.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below all major moving averages
  • Bearish MACD and low RSI
  • High short‑term volatility and decreasing volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Attractive dividend yield with sustainable payout
  • Defensive consumer‑staples sector
  • Strong cash flow despite elevated debt

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Stable dividend income
  • Potential for margin improvement and cost efficiencies
  • Low market‑beta reducing systemic risk

Key Metrics & Analysis

Financial Health

Revenue Growth5.40%
Profit Margin8.02%
P/E Ratio17.9
ROE7.18%
ROA2.02%
Debt/Equity49.62
P/B Ratio1.3
Op. Cash Flow$1.4B
Free Cash Flow$619.2M

Technical Analysis

TrendBearish
RSI37.9
Support$16.46
Resistance$17.49
MA 20$16.98
MA 50$17.28
MA 200$18.21
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14

Valuation

Fair Value$6.54
GradeOvervalued
TypeBlend
Dividend Yield2.55%

Risk Assessment

Beta0.11
Volatility21.29%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.